Company Overview of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber con...
11801 Research Drive
Alachua, FL 32615
Founded in 1999
Key Executives for Applied Genetic Technologies Corporation
Chief Executive Officer, President and Director
Total Annual Compensation: $313.9K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $175.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $336.2K
Senior Director of Process Development
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2014.
Applied Genetic Technologies Corporation Key Developments
Applied Genetic Technologies Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014
Feb 11 15
Applied Genetic Technologies Corporation announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported total revenue of $652,000 against $515,000 a year ago. Loss from operations was $4,702,000 against $2,905,000 a year ago. Investment income was $52,000 against $8,000 a year ago. Net loss was $4,650,000 or $0.28 per basic and diluted share against $735,000 or $6.74 per basic and diluted share a year ago. The lower net loss in 2013 includes favorable fair value adjustments associated with the company's former Series B purchase rights and warrant liabilities which resulted in the recognition of $2.2 million of other income.
For the six months, the company reported total revenue of $1,357,000 against $773,000 a year ago. Loss from operations was $10,111,000 against $4,871,000 a year ago. Investment income was $80,000 against $15,000 a year ago. Net loss was $10,031,000 or $0.63 per basic and diluted share against $7,799,000 or $71.55 per basic and diluted share a year ago.
Applied Genetic Technologies Corporation Appoints Stephen W. Potter as Vice President and Chief Business Officer
Jan 29 15
Applied Genetic Technologies Corporation announced the appointment of Stephen W. Potter as its Vice President and Chief Business Officer. In that role he will be responsible for corporate development for the company, including the commercialization of existing product candidates, exploring new opportunities for clinical stage assets, and business development initiatives. Mr. Potter, who has more than 15 years of experience as a senior executive in the biotechnology industry, succeeds Daniel L. Menichella, who resigned from his position at AGTC to pursue another opportunity. Mr. Potter was employed most recently by NeoStem Inc.
Applied Genetic Technologies Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM
Dec 17 14
Applied Genetic Technologies Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Sue Washer, President and CEO.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 1, 2014